Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-20

Study Completion Date

2019-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tobacco and alcohol are the two major risk factors for upper respiratory tract cancer (VADS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)

NCT03852238

Hepatocellular Carcinoma

COMPLETED

Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease

NCT03307408

Hepatocellular Carcinoma

UNKNOWN

Early Detection of Alcoholic Liver Disease

NCT04070508

Alcoholic Liver Disease Alcoholic Fibrosis of Liver Alcoholic Cirrhosis +5 more

WITHDRAWN

CHronic Hepatopathies Associated with ALcohol Consumption and MetAbolic Syndrome

NCT05623150

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Steatohepatitis Alcohol-related Liver Disease +2 more

RECRUITING

Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients

NCT04493814

NAFLD Type 2 Diabetes

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tobacco and alcohol are the two major risk factors for upper respiratory tract cancer (VADS). Among patients with VADS cancer, more than 60% reported daily alcohol consumption of more than 20 g / d. Such poisoning can be harmful, causing histological lesions of alcoholic liver disease, such as steatosis, alcoholic hepatitis, liver fibrosis and cirrhosis. In a population consuming more than 50 g of alcohol per day for 5 years, the prevalence of severe hepatic fibrosis is between 30% and 40%. In the therapeutic management of a cancer of VADS, the presence of cirrhosis is a prognostic element, increasing the postoperative risk of haemorrhage, surgical site infection and acute renal failure. The search for cirrhosis in the pre-therapeutic assessment is therefore important. The diagnosis of cirrhosis is not a problem when clinical, biological, radiological or endoscopic signs of hepatic insufficiency or portal hypertension are present. Asymptomatic cirrhosis is more difficult to diagnose without liver biopsy. Noninvasive hepatic exploration techniques have recently been developed and validated for the evaluation of liver fibrosis in the context of alcoholic liver disease. Fibroscan® (Echosens, Paris, France) is an imaging device for measuring the liver hardness (hepatic elasticity expressed in kPa), with a strong correlation with the presence of histological fibrosis of the liver. At the threshold of 19.5 kPa, Fibroscan can be used to diagnose cirrhosis with good diagnostic performance (Se 80%, Sp 90%, VPP 93%, VPN 70%) and good inter- and intra-observer reproducibility. Elastometry is a simple, reliable and non-invasive tool to systematically evaluate hepatic fibrosis in patients with VADS cancer. The examination can be performed during a routine care consultation. The post-therapeutic morbidity induced by cirrhosis in the cancers of VADS is not well known and there is no recommendation in France about the hepatic explorations to be carried out during the initial assessment of these neoplasias. It is essential to be able to specify this morbidity in order to adapt if necessary the therapeutic strategy of cancers of VADS.

The objective of this study is to systematically determine the presence of cirrhosis and / or liver fibrosis in patients with VADS cancer, in order to investigate their impact on the morbidity after treatment of squamous cell carcinomas of the head and neck.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Fibroses Liver Cirrhoses Squamous Cell Carcinoma of the Head and Neck

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

prevalence of cirrhosis

Study the prevalence of cirrhosis in patients with VADS cancer

Group Type OTHER

Evaluation of the hepatic fibrosis

Intervention Type OTHER

Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluation of the hepatic fibrosis

Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age
* Supported in the department of Orl \& CCF or Maxillo-Faciale surgery of the CHU d'Amiens
* Histological diagnosis of epidermoid carcinoma:

* From the oral cavity
* From the oropharynx
* Hypopharynx
* Larynx
* Any stage of cancer
* Affiliation to a social security scheme

Exclusion Criteria

* Patient already treated previously for a cancer of the VADS
* Patient referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No